CM338 for immunoglobulin A kidney disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests CM338 to see if it can help people with immunoglobulin A (IgA) nephropathy, a kidney condition. You may be able to join if you meet age, medication, and health criteria and can follow study safety rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You understand the study and agree by signing the consent form
- If pregnancy is possible for you, you will use reliable birth control during the study
- You did not take another investigational (research) drug in the 30 days before starting this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
This trial tests an experimental medicine called NM8074 for people with IgA nephropathy, a type of kidney disease. It aims to see if NM8074 can help protect your kidneys and reduce damage.
This study tests an investigational drug (SCTC21C) for people with a type of autoimmune kidney disease called IgA nephropathy. It aims to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests whether mycophenolate mofetil, an immunosuppressant drug, can reduce protein in the urine of people with IgA nephropathy that hasn't responded to other treatments. It aims to help slow down kidney damage.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.